Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression
- Jun Wei1,
- Jason Barr1,
- Ling-Yuan Kong1,
- Yongtao Wang1,
- Adam Wu1,
- Amit K. Sharma1,
- Joy Gumin1,
- Verlene Henry1,
- Howard Colman2,
- Raymond Sawaya1,
- Frederick F. Lang1 and
- Amy B. Heimberger1
- Authors' Affiliations: Departments of 1Neurosurgery and 2Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
- Corresponding Author:
Amy B. Heimberger, P.O. Box 301402, Unit 442, Houston, TX 77230-1402. Phone: 713-792-2400; Fax: 713-794-4950; E-mail: aheimber{at}mdanderson.org.
-
Parts of these data were presented at the American Society of Clinical Oncology Annual Meeting, May 2008, Chicago, Illinois and AACR Special Conference in Cancer Research: Tumor Immunology, December 2008, Miami, Florida.
Abstract
Purpose: Glioblastoma multiforme is a lethal cancer that responds poorly to therapy. Glioblastoma multiforme cancer-initiating cells have been shown to mediate resistance to both chemotherapy and radiation; however, it is unknown to what extent these cells contribute to the profound immunosuppression in glioblastoma multiforme patients and if strategies that alter their differentiation state can reduce this immunosuppression.
Experimental Design: We isolated a subpopulation of cells from glioblastoma multiforme that possessed the capacity for self-renewal, formed neurospheres in vitro, were capable of pluripotent differentiation, and could initiate tumors in vivo. The immune phenotype of these cells was characterized including the elaboration of immunosuppressive cytokines and chemokines by ELISA. Functional immunosuppressive properties were characterized based on the inhibition of T-cell proliferation and effector responses, triggering of T-cell apoptosis, and induction of FoxP3+ regulatory T cells. On altering their differentiation state, the immunosuppressive phenotype and functional assays were reevaluated.
Results: We found that the cancer-initiating cells markedly inhibited T-cell proliferation and activation, induced regulatory T cells, and triggered T-cell apoptosis that was mediated by B7-H1 and soluble Galectin-3. These immunosuppressive properties were diminished on altering the differentiation of the cancer-initiating cells.
Conclusion: Cancer-initiating cells contribute to tumor evasion of the immunosurveillance and approaches that alter the differentiation state may have immunotherapeutic potential. Clin Cancer Res; 16(2); 461–73
Footnotes
-
- Received July 27, 2009.
- Revision received October 7, 2009.
- Accepted October 19, 2009.









